Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | TNKS | O95271 | 2/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23946283 | 0.81 | CRHR1 (0.47) | KDM4ECYP2C9CYP3A4L3MBTL1NTRK1 | |
| SCHEMBL23946247 | 0.79 | CRHR1 (0.42) | KDM4ECYP2C9CYP3A4MAPTL3MBTL1 | |
| SCHEMBL23946331 | 0.79 | DHODH (0.45) | KDM4ECYP2C9CYP3A4L3MBTL1NTRK1 | |
| SCHEMBL19169192 | 0.78 | MAOA (0.46) | CYP1A2KDM4ECYP3A4MAPTL3MBTL1 | |
| SCHEMBL3664754 | 0.78 | ESR1 (0.50) | PARP1ESR1L3MBTL1NUDT1 | |
| SCHEMBL3242174 | 0.77 | PARP1 (0.47) | PARP1TNKSTNKS2CYP1A2ESR1 | |
| SCHEMBL7011032 | 0.77 | PARP1 (0.50) | PARP1TNKSTNKS2CYP1A2KDM4E | |
| SCHEMBL23946251 | 0.76 | CRHR1 (0.43) | KDM4ECYP2C9CYP3A4MAPTL3MBTL1 | |
| SCHEMBL19169646 | 0.75 | MAOA (0.44) | CYP1A2KDM4ECYP2C19CYP3A4MAPT | |
| SCHEMBL1773091 | 0.74 | NUDT1 (0.60) | KDM4EKMT2AMEN1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558585-B1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2013-09-25 | — | — | EP | disclosed |
| CN-1720238-B | Neurologically-active compounds | PRANA BIOTECHNOLOGY LTD | 2011-08-03 | — | — | CN | disclosed |
| EP-2210892-A2 | Neurologically-active compounds | Prana Biotechnology Limited (AU) | 2010-07-28 | — | — | EP | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| EP-1558585-A4 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2008-07-02 | — | — | EP | disclosed |
| US-20060167000-A1 | Neurologically-active compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| CN-1720238-A | Neurologically-active compounds | PRANA BIOTECHNOLOGY LTD (AU) | 2006-01-11 | — | — | CN | disclosed |
| EP-1558585-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | Prana Biotechnology Ltd (AU) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004031161-A1 | NEUROLOGICALLY-ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167000-A1 | Neurologically-active compounds | ACHE, PSEN1, PSEN2 | PARP1 2866/4885TNKS 2509/4885TNKS2 2610/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | PARP1 3308/4885TNKS 2808/4885TNKS2 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.